|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM23936080X |
| 003 |
DE-627 |
| 005 |
20231224115757.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2014 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2014.06.006
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0797.xml
|
| 035 |
|
|
|a (DE-627)NLM23936080X
|
| 035 |
|
|
|a (NLM)24947953
|
| 035 |
|
|
|a (PII)S1521-6616(14)00153-3
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Marwaha, Ashish K
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes
|
| 264 |
|
1 |
|c 2014
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.09.2014
|
| 500 |
|
|
|a Date Revised 08.04.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2014. Published by Elsevier Inc.
|
| 520 |
|
|
|a Type 1 diabetes (T1D) results from the autoimmune destruction of insulin-producing pancreatic beta cells. There is now mounting evidence that pro-inflammatory pathways, which are mediated by T cells that secrete IL-17 and IFN-γ, play a critical role in the loss of beta cells. These data suggest that blockade of T cells that secrete IL-17 and IFN-γ may halt or reverse disease in subjects with recent-onset T1D. Agents to facilitate this approach are currently in clinical use. Ustekinumab, a humanized monoclonal antibody that targets the shared p40 subunit of IL-12 and IL-23, has been used for the treatment of psoriasis, an indication for which it has proven to be safe and effective. In this review, we summarize the evidence that supports a combined pathogenic role of IL-17 and IFN-γ in the development of T1D, with the aim of providing a rationale for testing agents such as ustekinumab for the treatment of T1D
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Clinical trial
|
| 650 |
|
4 |
|a IFN-γ;
|
| 650 |
|
4 |
|a IL-17;
|
| 650 |
|
4 |
|a Stelara;
|
| 650 |
|
4 |
|a Type 1 diabetes;
|
| 650 |
|
4 |
|a Ustekinumab;
|
| 650 |
|
7 |
|a Antibodies, Monoclonal, Humanized
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-17
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 650 |
|
7 |
|a Ustekinumab
|2 NLM
|
| 650 |
|
7 |
|a FU77B4U5Z0
|2 NLM
|
| 700 |
1 |
|
|a Tan, Sara
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dutz, Jan P
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 154(2014), 1 vom: 19. Sept., Seite 84-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:154
|g year:2014
|g number:1
|g day:19
|g month:09
|g pages:84-9
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2014.06.006
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 154
|j 2014
|e 1
|b 19
|c 09
|h 84-9
|